These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35268499)

  • 1. Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center.
    Costantino M; Sellitto C; Conti V; Corbi G; Marongiu F; Genovese G; Moccia G; Capunzo M; Borrelli A; Pagliano P; Farroni M; Lombardi GM; Elberti MG; Filippelli A; De Caro F
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
    Wi YM; Kim SH; Peck KR
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can reactogenicity predict immunogenicity after COVID-19 vaccination?
    Hwang YH; Song KH; Choi Y; Go S; Choi SJ; Jung J; Kang CK; Choe PG; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2021 Nov; 36(6):1486-1491. PubMed ID: 34038996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study.
    Romero-Ibarguengoitia ME; González-Cantú A; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; Barco-Flores IA; González-Facio R; Sanz-Sánchez MÁ
    Vaccines (Basel); 2022 Jul; 10(7):. PubMed ID: 35891303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.
    Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G
    Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.
    Ferrara P; Ponticelli D; Losa L; Romeo C; Magliuolo R; Vitale A; Zampella A; Alleanza L; Borrelli M; Schiavone B; Mantovani LG
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Adverse Effects of COVID-19 Vaccines Experienced by Healthcare Workers at Guizhou Provincial Staff Hospital, China.
    Wei Y; Wang Y; Liu L; Zha Y; Yang Y; Wang Y; Roberts N; Li Y
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance.
    Montalti M; Soldà G; Di Valerio Z; Salussolia A; Lenzi J; Forcellini M; Barvas E; Guttmann S; Messina R; Poluzzi E; Raschi E; Riccardi R; Fantini MP; La Fauci G; Gori D;
    EClinicalMedicine; 2021 Aug; 38():101027. PubMed ID: 34505029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [
    Cohen D; Krauthammer SH; Wolf I; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1854-1863. PubMed ID: 33774684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of Adverse Events Following Immunization (AEFI) after Third Dose Booster Vaccination with mRNA-Based Vaccine in Universitas Indonesia Hospital Health Personnel.
    Hidayat R; Mustika AP; Avisha F; Djuliannisaa Z; Winari DD; Putri RA; Lisman HM; Davin V; Widhani A; Aini MH; Rahmadani M; Istanti ND; Giantini A
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.
    Gold MS; Lincoln G; Cashman P; Braunack-Mayer A; Stocks N
    Vaccine; 2021 Jan; 39(2):332-342. PubMed ID: 33279317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
    Littlejohn ES; Clothier HJ; Perrett KP; Danchin M
    Hum Vaccin Immunother; 2015; 11(7):1828-35. PubMed ID: 26075435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.
    Dutta S; Kaur R; Charan J; Bhardwaj P; Ambwani SR; Babu S; Goyal JP; Haque M
    Cureus; 2022 Jan; 14(1):e21376. PubMed ID: 35198288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.
    García-Grimshaw M; Ceballos-Liceaga SE; Hernández-Vanegas LE; Núñez I; Hernández-Valdivia N; Carrillo-García DA; Michel-Chávez A; Galnares-Olalde JA; Carbajal-Sandoval G; Del Mar Saniger-Alba M; Carrillo-Mezo RA; Fragoso-Saavedra S; Espino-Ojeda A; Blaisdell-Vidal C; Mosqueda-Gómez JL; Sierra-Madero J; Pérez-Padilla R; Alomía-Zegarra JL; López-Gatell H; Díaz-Ortega JL; Reyes-Terán G; Arauz A; Valdés-Ferrer SI
    Clin Immunol; 2021 Aug; 229():108786. PubMed ID: 34147649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.